DR. SIMON P. HORSLEN, MB CHB

PITTSBURGH, PA

Research Active
Pediatrics - Pediatric Gastroenterology NPI registered 20+ years 50 publications 2022 – 2026 NPI: 1750471645

Practice Location

4401 PENN AVE # 6130
PITTSBURGH, PA 15224-1334

Phone: (412) 692-5676

What does SIMON HORSLEN research?

Simon P Horslen studies various aspects of pediatric liver and intestinal diseases, particularly conditions like biliary atresia and neonatal short bowel syndrome. He investigates how social factors, like race and community wealth, influence treatment and outcomes for children, aiming to reduce disparities in healthcare access. Additionally, he explores treatment options, such as the use of specific medications for inflammatory bowel disease in children with liver issues, and analyzes the financial implications of these medical procedures to improve support for affected families.

Key findings

  • In biliary atresia, Black infants were about 9 days older at surgery compared to white infants, indicating significant disparities in access to timely care.
  • Children receiving ABO incompatible liver transplants waited an average of 11 days for a transplant, versus 113 days for those with ABO compatible donors, showing a potential to reduce waitlist mortality.
  • The average hospital stay for children with neonatal short bowel syndrome was 150 days at a cost of approximately $529,000, with non-Hispanic Black children staying 16 days longer than their non-Hispanic White counterparts.
  • Matrix metalloproteinase-7 levels were found to distinguish biliary atresia from other liver conditions with 94% accuracy, facilitating faster diagnosis.
  • Oral vancomycin led to over five times higher rates of clinical remission in children with inflammatory bowel disease associated with primary sclerosing cholangitis after one year.

Frequently asked questions

Does Dr. Horslen study biliary atresia?
Yes, Dr. Horslen conducts research on biliary atresia, focusing on demographic factors affecting treatment outcomes.
What treatments has Dr. Horslen researched?
He has researched the effectiveness of oral vancomycin for inflammatory bowel disease and the impact of ABO incompatible liver transplants on waitlist mortality.
Is Dr. Horslen's work relevant to families with children needing organ transplants?
Yes, his research addresses pediatric organ transplant practices and costs, providing insights that can help families navigate healthcare resources.
How does race affect pediatric liver treatment outcomes according to Dr. Horslen's research?
His studies have shown that race can significantly impact when children receive surgeries and their overall healthcare access.
What are some of the financial challenges related to pediatric intestinal transplants?
Dr. Horslen's research indicates that the costs of intestinal transplants can be very high, averaging around $263,724, which poses significant financial challenges for families.

Publications in plain English

Predicting Post-intestinal Transplant Patient Survival Based on A Priori Data.

2026

Transplantation

Weiss SA, Schnellinger E, Foutz J, Shah S, Jafri SM +2 more

Plain English
This study looked at factors that predict how long patients might survive after receiving an intestinal transplant, using data from 567 patients who had the procedure between 2016 and 2021. They found that older age, repeat infections before the transplant, and needing a liver transplant at the same time were linked to lower survival rates, while lower bilirubin levels indicated a better chance of survival. This information is crucial because it helps doctors and patients decide when the benefits of getting an intestinal transplant outweigh the risks. Who this helps: This helps patients with intestinal failure and their healthcare providers.

PubMed

Demographic Factors and Biliary Atresia: A Childhood Liver Disease Research Network Study.

2026

Pediatrics

Kastenberg ZJ, Beil CA, Henn L, Alonso EM, Hsu EK +16 more

Plain English
Researchers studied how factors like race, community wealth, and ethnicity affect treatment outcomes for infants with biliary atresia, a serious liver disease. They found that Asian and Hispanic infants were less likely to receive a vital surgery, and those from poorer communities tended to have surgery at older ages. Specifically, Black infants were about 9 days older at surgery compared to white infants. Understanding these patterns is important because they highlight disparities in healthcare access and can help ensure all infants get timely treatment to improve their chances of liver survival.

PubMed

Interleukin 8-CXCR2-mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap-induced stellate cell activation.

2025

Hepatology (Baltimore, Md.)

Luo Y, Fraser L, Jezykowski J, Gupta NA, Miethke AG +14 more

Plain English
This study focused on biliary atresia (BA), a serious liver condition in infants marked by inflammation and scarring. Researchers found that in patients with BA, certain immune cells called neutrophils were overly active, producing structures known as neutrophil extracellular traps (NETs), which were increased by 70% in BA cases compared to healthy controls. These NETs activated liver cells that contribute to fibrosis, meaning they could worsen liver damage and potentially lead to the need for a transplant. Who this helps: This research aids doctors treating infants with biliary atresia, helping them understand how to better manage the disease.

PubMed

Increased serum GM-CSF at diagnosis of biliary atresia is associated with improved biliary drainage.

2025

Pediatric research

Taylor SA, Harpavat S, Gromer KD, Andreev V, Loomes KM +13 more

Plain English
This study looked at infants with biliary atresia (BA) to find out if certain immune system markers could predict how well their bile duct surgery would work. They found that higher levels of a protein called GM-CSF in the blood at the time of diagnosis were linked to better bile flow after surgery, with a strong predictive ability (an accuracy score of 0.84). These findings are important because they could help doctors tailor treatments more effectively based on early blood test results. Who this helps: This benefits infants with biliary atresia and their doctors.

PubMed

OPTN/SRTR 2023 Annual Data Report: Intestine.

2025

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Horslen SP, Raghu VK, Ahn YS, Howell J, Schumacher B +3 more

Plain English
This report looked at the state of intestine transplants in 2023, revealing that 135 patients joined the waiting list. While there were no deaths on the list for those needing a transplant without a liver, 8 patients died while waiting for an intestine and liver transplant. The study also found that 95 transplants were performed that year, with survival rates for the transplants being about 46.5% for adults and 52.2% for children after five years. Who this helps: This information benefits patients in need of intestine transplants and their doctors.

PubMed

Plasma proteome correlations with liver stiffness in pediatric cholestasis implicate epithelial to mesenchymal transition.

2025

Hepatology communications

Shneider BL, Kanchi RS, Grimm SL, Devaraj S, Emamaullee J +18 more

Plain English
This study looked at the relationship between proteins in the blood and liver stiffness in children with certain liver diseases, specifically biliary atresia, alpha-1 antitrypsin deficiency, and Alagille syndrome. The researchers found thousands of proteins in the blood that were linked to liver stiffness, with a strong correlation in biliary atresia (a score of 0.79). This is important because it helps identify potential biomarkers for liver damage and highlights a specific biological process that might contribute to the disease's progression. Who this helps: This helps doctors and researchers working with children suffering from liver diseases.

PubMed

Outcome After Intestinal Transplantation From Living Versus Deceased Donors: A Propensity-matched Cohort Analysis of the International Intestinal Transplant Registry: Erratum.

2025

Annals of surgery

Ceulemans LJ, Dubois A, Clarysse M, Canovai E, Venick R +10 more

PubMed

Social and Financial Costs of Neonatal Intestinal Failure.

2025

JAMA network open

Raghu VK, Belaid S, Gutierrez S, Holzer P, Orris S +11 more

Plain English
This study examined the length of hospital stays and costs for children with a rare condition called neonatal short bowel syndrome, focusing on how factors like race and neighborhood opportunities affected these outcomes. Researchers found that among the 2,267 children studied, the average hospital stay was 150 days, costing about $529,000. Notably, non-Hispanic Black children stayed in the hospital 16 days longer than non-Hispanic White children, highlighting significant disparities that indicate a need for better support and resources for affected families.

PubMed

ABO Incompatible Grafts Are Associated With Excellent Outcomes in Pediatric Liver Transplant Recipients: An Important Resource to Reduce Waitlist Mortality.

2025

Pediatric transplantation

Valentino PL, Healey PJ, Perkins JD, Desai B, Quezada H +10 more

Plain English
This study looked at liver transplants in children, comparing those who received organs from donors with a different blood type (ABO incompatible) to those with matching blood types (ABO compatible). Researchers found that children who received ABO incompatible transplants waited much less time for a liver, averaging just 11 days compared to 113 days for ABO compatible transplants. While there were slightly more cases of bile duct problems in the ABO incompatible group, overall survival rates and complications were similar for both groups, highlighting the potential of ABO incompatible organs to help reduce waitlist deaths among children needing liver transplants.

PubMed

Trends in the Perioperative Practices for Immunological Assessment and Immunosuppression Strategies for Patients Undergoing Intestinal Transplantation at American Transplant Centers.

2025

Transplantation proceedings

Abusuliman M, Jafri SM, Summers BB, Beduschi T, Boike J +15 more

Plain English
This study looked at how major transplant centers in the U.S. assess and manage immune system issues for patients undergoing intestinal transplants. Researchers surveyed ten centers, finding that while all used similar processes for testing before and after transplants, there was a wide range in how they handled specific treatments for immune responses, such as desensitization and managing rejection. Standardizing these practices is essential because it could lead to better health outcomes for patients receiving these complex surgeries.

PubMed

Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant.

2025

Pediatric transplantation

Raghu VK, Rothenberger SD, Squires JE, Eisenberg E, Peters AL +11 more

Plain English
This study looked at how different liver transplant centers manage medications given to children right after they receive a transplant. It found that centers with more consistent medication practices had a significantly lower likelihood—2.72 times less likely—of the child experiencing organ rejection within the first year. Understanding and reducing differences in these medication approaches could help improve transplant outcomes for kids.

PubMed

Cardiac MRI-Derived Inferior Vena Cava Cross-Sectional Area Correlates with Measures of Fontan-Associated Liver Disease.

2024

Pediatric cardiology

Gunsaulus M, Wang L, Haack L, Christopher A, Feingold B +11 more

Plain English
This study looked at how the size of a specific blood vessel (the inferior vena cava) in post-surgery patients impacts the severity of liver disease associated with a heart condition called Fontan. Researchers found that a larger cross-sectional area of the inferior vena cava was linked to higher levels of liver-related markers, such as Gamma-Glutamyl Transferase (GGT) and a Fibrosis score, as well as ultrasound signs of cirrhosis. This is important because it suggests that measuring this blood vessel size can help doctors better identify patients who may be at risk for serious liver problems without needing invasive tests. Who this helps: Patients who have undergone Fontan surgery may benefit from improved monitoring of their liver health.

PubMed

Enhanced Donor Antigen Presentation by B Cells Predicts Acute Cellular Rejection and Late Outcomes After Transplantation.

2024

Transplantation direct

Ashokkumar C, Ningappa M, Raghu V, Mazariegos G, Higgs BW +13 more

Plain English
This study looked at how well B cells (a type of immune cell) present donor antigens in transplant patients, and found that a higher "antigen presenting index" (API) predicted acute cellular rejection (ACR) of organ transplants. In their analysis of 138 transplant recipients, those who experienced rejection had an average API of 2.2, compared to 0.6 for those who did not reject their transplant. This is important because knowing the API can help doctors identify which patients are at higher risk for rejection and other complications after receiving a transplant. Who this helps: This helps transplant patients and their doctors by improving the prediction of organ rejection.

PubMed

OPTN/SRTR 2022 Annual Data Report: Intestine.

2024

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Horslen SP, Ahn YS, Wood NL, Schnellinger EM, Gauntt K +1 more

Plain English
This report looks at intestinal transplants, which are the least common organ transplants despite being helpful for people with severe intestinal failure. In 2022, only 82 intestine transplants were performed, slightly above the record low, and the number of new patients on the waiting list was only 146. While the transplant rate for adults has dropped to 55.6 transplants per 100 years, kids generally see more consistent rates at 22.8 per 100 years, and the risks are higher for those needing both intestine and liver transplants. Who this helps: This information benefits patients waiting for transplants, especially children and adults needing intestinal transplants.

PubMed

From intestinal failure to transplantation: Review on the current need for transplant indications under multidisciplinary transplant programs worldwide.

2024

Pediatric transplantation

Raghu VK, Rumbo C, Horslen SP

Plain English
This study looked at how children with intestinal failure—where their digestive system doesn't work well enough to get nutrition through normal eating—are treated, especially regarding when they might need a transplant. The authors found that advances in medical care have led to better survival rates without needing a transplant, with a notable decrease in the number of children requiring transplantation. However, some children still need these transplants when other treatments aren't effective or when they can’t handle the demands of long-term feeding through tubes. Who this helps: This helps children with intestinal failure and their families, as well as the doctors caring for them.

PubMed

Sepsis during short bowel syndrome hospitalizations: Identifying trends, disparities, and clinical outcomes in the United States.

2024

World journal of gastrointestinal pathophysiology

Dahiya DS, Wachala J, Solanki S, Solanki D, Kichloo A +11 more

Plain English
This study looked at hospitalizations for short bowel syndrome (SBS) in adults and how often these cases were complicated by sepsis, a serious infection. Out of 247,097 SBS hospitalizations from 2005 to 2014, about 21.7% involved sepsis, and this rate increased from 20.8% to 23.5% over that time period. Patients with septic SBS were more likely to be male, younger, or from minority groups, and they had a higher death rate of 8.5% compared to 1.4% for those without sepsis. Who this helps: This information helps doctors understand the risks associated with SBS and improve care for affected patients.

PubMed

Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2024

The lancet. Gastroenterology & hepatology

Miethke AG, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P +31 more

Plain English
This study looked at a new medication called maralixibat for children with progressive familial intrahepatic cholestasis (PFIC), a liver disease that causes severe itching and other issues. The trial involved 93 participants, and those taking maralixibat experienced a significant improvement in itching, with a score reduction of about 1.7 points compared to 0.6 for those on a placebo. Additionally, bile acid levels dropped by an average of 176 micromoles per liter in the maralixibat group, while they increased in the placebo group. Who this helps: This research benefits children suffering from PFIC and their families by offering a new treatment option.

PubMed

Evolution of intestinal and multivisceral transplantation: A thirty-year United States perspective.

2024

Intestinal Failure (New York, N.Y.)

Samoylova ML, Kesseli SJ, Park C, Yerxa J, Horslen S +8 more

Plain English
This study looked at how intestinal transplants in the U.S. have evolved over the past 30 years, focusing on changes in the number of surgeries and survival rates for patients. Overall, there were 3,035 transplants from 1990 to 2020, with the number increasing significantly over time: from 398 in the first decade to 1,235 in the last. It found that while more adults are receiving these transplants (from 35% to 59%), survival rates have improved for children, but have not changed much for adults, showing a need for better long-term care for adult patients. Who this helps: This research helps patients, especially adults needing intestinal transplants, and their doctors seeking to improve outcomes.

PubMed

Introduction to the 13th pediatric intestinal failure and rehabilitation symposium (PIFRS) special edition.

2024

Intestinal Failure (New York, N.Y.)

Rudolph J, Horslen S, Mazariegos G

PubMed

Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.

2024

Hepatology (Baltimore, Md.)

Squires JE, Horslen SP

PubMed

Protein biomarkers GDF15 and FGF21 to differentiate mitochondrial hepatopathies from other pediatric liver diseases.

2024

Hepatology communications

Van Hove JLK, Friederich MW, Strode DK, Van Hove RA, Miller KR +23 more

Plain English
This study examined two proteins, GDF15 and FGF21, to see if they could help identify mitochondrial hepatopathies (MH), a type of liver disease in children, compared to other liver conditions. Researchers found that GDF15 and FGF21 levels were significantly higher in children with MH than those with other liver diseases, showing a strong ability to identify MH cases (with an accuracy of 88% sensitivity and 96% specificity when both markers were elevated). These findings are important because they provide a way to differentiate MH from other liver diseases, which can help in early diagnosis and management, potentially improving outcomes for affected children.

PubMed

Equipoise in pediatric acute liver failure.

2024

Journal of pediatric gastroenterology and nutrition

Chapin CA, Squires JE, Horslen SP, Alonso EM

PubMed

Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.

2024

Hepatology (Baltimore, Md.)

Pandurangi S, Mourya R, Nalluri S, Fei L, Dong S +17 more

Plain English
This study looked at the blood protein matrix metalloproteinase-7 (MMP-7) to see if it can accurately identify biliary atresia (BA) in infants with liver issues. Researchers tested 399 infants and found that MMP-7 levels can effectively distinguish BA from other liver conditions, achieving a 94% accuracy rate for identifying those with BA at a specific cutoff level. This finding is important because using MMP-7 could make diagnosing BA easier and faster, potentially leading to quicker treatment for affected infants.

PubMed

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.

2024

Alimentary pharmacology & therapeutics

Ricciuto A, Liu K, El-Matary W, Amin M, Amir AZ +34 more

Plain English
This study looked at how effective oral vancomycin is in treating inflammatory bowel disease (IBD) in children with a liver condition called primary sclerosing cholangitis (PSC). Researchers found that patients taking vancomycin were more than five times more likely to experience clinical remission of IBD after one year compared to those who did not take the medication. This is important because finding effective treatments for IBD can significantly improve the quality of life for these young patients.

PubMed

Impact of early immunosuppression on pediatric liver transplant outcomes within 1 year.

2024

Journal of pediatric gastroenterology and nutrition

Raghu VK, Zhang X, Squires JE, Eisenberg E, Feldman AG +9 more

Plain English
This study looked at how different early treatments to suppress the immune system affect the success of liver transplants in kids during their first year after surgery. It found that using a type of antibody called T-cell depleting antibodies can improve chances of survival in some cases but may also increase risks in others, showing contrasting results in two data sources. Overall, the research highlights the need for better teamwork among hospitals to find the best treatment strategies for these young patients.

PubMed

Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease.

2023

Hepatology (Baltimore, Md.)

Leung DH, Devaraj S, Goodrich NP, Chen X, Rajapakshe D +132 more

Plain English
This study looked at specific biological markers in children with liver diseases to see how they relate to liver stiffness, which indicates fibrosis or scarring. In children with biliary atresia, the study found that markers such as IL-8, endoglin, and MMP-7 were linked to increased liver stiffness, helping improve predictions of liver condition severity. For children with alpha-1 antitrypsin deficiency, the marker CTGF was linked to lower liver stiffness, enhancing predictive accuracy further. Who this helps: This research benefits doctors and healthcare providers working with children suffering from cholestatic liver diseases, aiding them in diagnosing and assessing liver health more effectively.

PubMed

Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy.

2023

Hepatology (Baltimore, Md.)

Harpavat S, Hawthorne K, Setchell KDR, Rivas MN, Henn L +18 more

Plain English
This study looked at how serum bile acid levels can predict health outcomes in infants with biliary atresia who had surgery called Kasai portoenterostomy (KP). Researchers found that infants with lower bile acid levels (40 µmol/L or less) had significantly better health at age two, with only an 8.5% chance of needing a liver transplant or dying over ten years, compared to a 42.9% chance for those with higher bile acid levels. This information is important because it can help doctors better predict which infants may face more serious health issues after surgery. Who this helps: This helps doctors and healthcare providers manage care for infants with biliary atresia.

PubMed

An analysis of the outcomes of Clostridioides difficile occurring in intestinal transplant recipients requiring hospitalization.

2023

Transplant infectious disease : an official journal of the Transplantation Society

Amjad W, Schiano T, Segovia MC, Malik A, Weiner J +2 more

Plain English
This study looked at the impact of Clostridioides difficile infection (CDI) in patients who have received intestinal transplants. Out of over 8,400 hospitalizations, 320 had CDI, leading to longer hospital stays (7 days compared to 5 days for those without CDI) and higher costs (around $54,430 vs. $48,888). It matters because CDI is a major reason for readmission among these patients, making their recovery and care more complicated and expensive. Who this helps: This research benefits healthcare providers and intestinal transplant patients by highlighting the risks and costs associated with CDI.

PubMed

Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency.

2023

JHEP reports : innovation in hepatology

Felzen A, van Wessel DBE, Gonzales E, Thompson RJ, Jankowska I +68 more

Plain English
This study looked at how different genetic mutations affect the severity of bile salt export pump (BSEP) deficiency, a condition that often requires liver transplants in children. Researchers found that patients with one mild mutation (p.D482G or p.E297G) combined with a severe mutation faced a similar poor prognosis as those with two severe mutations. Specifically, only 21% of these patients had a functioning liver by age 10, showing that they do not respond well to surgeries that could help. Who this helps: This information benefits doctors and families of affected children, as it clarifies which patients are unlikely to improve with certain treatments.

PubMed

OPTN/SRTR 2021 Annual Data Report: Intestine.

2023

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Horslen SP, Wood NL, Cafarella M, Schnellinger EM

Plain English
This report looks at the state of intestine transplants over the past 30 years. It found that while there was a peak in demand for these transplants until 2007, the number of people waiting for and receiving these transplants has been declining in recent years, particularly for adults needing both an intestine and liver transplant. The research also showed that transplant survival rates haven't improved, with 1-year failure rates at 21.6% for intestine-only transplants and 28.6% for combined intestine-liver transplants. Who this helps: This information benefits patients needing intestine transplants and their healthcare providers.

PubMed

Outcome After Intestinal Transplantation From Living Versus Deceased Donors: A Propensity-matched Cohort Analysis of the International Intestinal Transplant Registry.

2023

Annals of surgery

Ceulemans LJ, Dubois A, Clarysse M, Canovai E, Venick R +10 more

Plain English
This study looked at the outcomes of intestinal transplants from living donors compared to those from deceased donors. Out of 4,156 transplants analyzed, only 76 were from living donors, and the results showed similar survival rates: one-year survival was 74.2% for living donors and 80.3% for deceased donors, with no significant differences in rejection rates or long-term survival. These findings suggest that living donations can be just as effective as deceased donations for patients with severe intestinal failure. Who this helps: Patients needing intestinal transplants can consider living donations as a viable option.

PubMed

Outcome of Children with Transjugular Intrahepatic Portosystemic Shunt: A Meta-Analysis of Individual Patient Data.

2023

Cardiovascular and interventional radiology

Deniz S, Schinner R, Monroe EJ, Horslen S, Srinivasa RN +16 more

Plain English
This study looked at how well children do after undergoing a procedure called transjugular intrahepatic portosystemic shunt (TIPS), which helps relieve pressure in the liver. It found that out of 135 children studied, those with fluid in the abdomen (ascites) had a poorer chance of living without needing a liver transplant, with a 2.3 times higher risk compared to those without it. This information is important because it helps doctors understand which patients may have worse outcomes, allowing for better care and treatment plans. Who this helps: This helps doctors and pediatric patients with liver conditions.

PubMed

Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes.

2023

Journal of hepatology

Glessner JT, Ningappa MB, Ngo KA, Zahid M, So J +30 more

Plain English
This study looked into the genetic causes of biliary atresia (BA), a rare liver disease that often requires a liver transplant in children. Researchers found significant genetic variants in two specific genes, AFAP1 and TUSC3, that are linked to problems in cell movement and organization during development. The study identified that BA is associated with both common and rare genetic mutations that disrupt normal liver development, highlighting the potential for preventive strategies against this condition. Who this helps: This helps children with biliary atresia and their families by improving understanding of the disease and guiding prevention efforts.

PubMed

Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease.

2023

Hepatology communications

Boster JM, Goodrich NP, Spino C, Loomes KM, Alonso EM +14 more

Plain English
This study looked at muscle mass in school-aged children with specific genetic liver diseases, focusing on those with intrahepatic cholestasis. Researchers found that about 33% of children with chronic intrahepatic cholestasis and 41% with Alagille syndrome had low muscle mass (sarcopenia), which is significantly worse than those with other liver issues. These muscle issues were linked to poorer quality of life, indicating that addressing muscle health in these children is important for their overall well-being. Who this helps: This helps children with liver diseases, their families, and doctors treating them.

PubMed

Neonatal cholestasis in children with Alpha-1-AT deficiency is a risk for earlier severe liver disease with male predominance.

2023

Hepatology communications

Teckman J, Rosenthal P, Ignacio RV, Spino C, Bass LM +13 more

Plain English
This study looked at how Alpha-1-antitrypsin deficiency (AATD) affects liver health in children, particularly focusing on those who develop a condition called neonatal cholestasis. The researchers found that 65% of infants with neonatal cholestasis were male, and 41% of these infants progressed to more severe liver problems by about 5 months old. This is important because it highlights the need for early monitoring and nutritional support for these children to prevent serious complications later on. Who this helps: This helps patients, their families, and doctors managing liver health in infants with Alpha-1 antitrypsin deficiency.

PubMed

Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children.

2023

Hepatology communications

Squires JE, Miethke AG, Valencia CA, Hawthorne K, Henn L +21 more

Plain English
Researchers studied liver conditions in children caused by problems in their mitochondria, categorizing them into three groups: those with acute liver failure, chronic liver disease, and those who had liver transplants. They found that younger children with acute liver failure were more likely to have a specific mitochondrial issue (77% of cases) compared to those with chronic liver disease (41%). This research is important because it reveals significant differences in diagnosis and survival rates, emphasizing the importance of quick genetic testing to improve treatment options and outcomes for these children.

PubMed

Pediatric intestine transplant cost: Analysis of the Pediatric Health Information System database.

2023

JPEN. Journal of parenteral and enteral nutrition

Raghu VK, Rothenberger SD, Rudolph JA, Mazariegos GV, Horslen SP +1 more

Plain English
The study looked at the costs of intestine transplants for children between 2004 and 2020, analyzing data from 376 patients. It found that the average cost from surgery to discharge was about $263,724, and patients stayed in the hospital for around 52 days. Costs were higher for those needing liver transplants and specific medications, highlighting that intestine transplants are expensive and lengthy procedures, which is important for planning healthcare resources and patient support.

PubMed

Advancing the Field of Pediatric Liver Transplantation: Urgent Action Items Identified During the 2022 Society of Pediatric Liver Transplantation Meeting.

2023

Transplantation

Feldman AG, Adams M, Griesemer AD, Horslen S, Kelly B +9 more

PubMed

Child self-reported quality of life in pediatric intestinal failure.

2022

Journal of pediatric surgery

Wong M, Neam VC, Horslen SP, Faino A, Javid PJ

Plain English
This study looked at how children with intestinal failure feel about their quality of life, which is important for understanding their health from their own perspective. Researchers found that 69 children between ages 5 and 10 reported feeling better about their lives as they got older, but their scores were still lower than those of healthy children and some chronically ill kids. Specifically, children with shorter bowel lengths reported lower quality of life, indicating that their physical health can greatly affect how they feel overall. Who this helps: This helps patients with intestinal failure and their families.

PubMed

OPTN/SRTR 2020 Annual Data Report: Intestine.

2022

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Horslen SP, Smith JM, Weaver T, Cafarella M, Foutz J

Plain English
This research looked at intestine transplants in the U.S. over the last year. Although the number of people waiting for an intestine transplant has slightly increased, the overall number of transplants and transplant rates are declining. Notably, while patient survival rates at one year after surgery are improving, survival rates at three and five years have not changed much. Who this helps: This information benefits patients waiting for intestine transplants and their doctors by providing insights into current trends and outcomes.

PubMed

Risk of variceal hemorrhage and pretransplant mortality in children with biliary atresia.

2022

Hepatology (Baltimore, Md.)

Bass LM, Ye W, Hawthorne K, Leung DH, Murray KF +15 more

Plain English
This research studied the risk of severe bleeding and death before liver transplants in children with a condition called biliary atresia, focusing on 869 kids over several years. They found that 9.4% of younger children and 8% of older children experienced their first bleeding episode within five years. Additionally, the survival rate without needing a transplant was 45.1% for younger kids and 79.2% for older ones, showing that while there is some risk of bleeding, most children have a fair chance of surviving without immediate transplant needs. Who this helps: This information benefits doctors and healthcare providers in managing and monitoring children with biliary atresia.

PubMed

CAQ Corner: Genetic liver disease.

2022

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Squires JE, Horslen SP

PubMed

Use of funded multicenter prospective longitudinal databases to inform clinical trials in rare diseases-Examination of cholestatic liver disease in Alagille syndrome.

2022

Hepatology communications

Shneider BL, Kamath BM, Magee JC, Goodrich NP, Loomes KM +13 more

Plain English
This study looked at children with Alagille syndrome, a rare condition that can lead to liver disease, to gather real-world data that could help improve clinical trials for new treatments. Researchers followed 59 children and found that after two years, there was a significant reduction in itching (averaging a decrease of 1.43 points) while certain liver function indicators remained stable, though platelet counts decreased significantly. This research is important because it provides valuable information that can better inform future treatments for rare diseases like Alagille syndrome. Who this helps: This helps patients with Alagille syndrome and their doctors.

PubMed

Immunosuppression Regimens for Intestinal Transplantation in Children.

2022

Paediatric drugs

Raghu VK, Vetterly CG, Horslen SP

Plain English
This study looks at how to manage medications that prevent the body from rejecting transplanted intestines in children. Researchers found that using specific drugs like antithymocyte globulin and basiliximab during the first phase of treatment, along with regular drugs like tacrolimus, can help reduce complications such as rejection and infections. Improved medication management is important because it can lead to better outcomes and fewer side effects for kids undergoing these complex surgeries. Who this helps: Patients and their families in need of intestinal transplants.

PubMed

Analysis of transition from intravenous iron sucrose to ferric carboxymaltose infusions in pediatric patients with intestinal failure.

2022

JPEN. Journal of parenteral and enteral nutrition

Kaenkumchorn TK, Rosete BE, Carlin K, Fukasawa S, Horslen SP +1 more

Plain English
This study looked at how well two types of iron infusions—iron sucrose (IS) and ferric carboxymaltose (FCM)—work for children with intestinal failure (IF). Researchers found that while both treatments effectively maintained important blood and iron levels, patients taking FCM needed far fewer infusions (only 2 on average) compared to those on IS (15 infusions). This is significant because it means patients can receive treatment less frequently without compromising their health, making life easier for them and their families. Who this helps: This helps pediatric patients with intestinal failure and their caregivers.

PubMed

Current practices in lipid emulsion utilization in the prevention and treatment of intestinal failure-associated liver disease: A survey of pediatric intestinal rehabilitation and transplant centers.

2022

JPEN. Journal of parenteral and enteral nutrition

Raghu VK, Sevilla WMA, King DE, Alissa F, Rothenberger S +3 more

Plain English
This study looked at how different types of intravenous lipid emulsions (ILEs) are used in treating children with liver disease related to intestinal failure. Researchers found that 85% of centers preferred using a type called SMOF-ILE for new patients, but when patients showed liver issues, 56% switched to a different option called FO-ILE instead. This shift is important because it shows that healthcare providers are moving toward better treatment options that could improve liver health for affected children. Who this helps: This helps pediatric patients with intestinal failure and their doctors.

PubMed

Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome.

2022

Hepatology communications

Shneider BL, Spino CA, Kamath BM, Magee JC, Ignacio RV +18 more

Plain English
The study looked at how the drug maralixibat affects children with severe cholestasis caused by Alagille syndrome. After 48 weeks, children taking maralixibat showed significant improvements in itching and quality of life scores, with their itching severity scores dropping by about 1.6 points and quality of life increasing by over 10 points. This is important because it indicates that maralixibat can help manage symptoms and improve daily living for these children. Who this helps: This benefits children with Alagille syndrome and their families.

PubMed

The Effect of the COVID-19 Pandemic in Intestinal Rehabilitation and Transplant Patients: Initial Results of the Intestinal Rehabilitation and Transplant Association's International Survey.

2022

Transplantation

Segovia M, Fernandez MF, Rumbo C, Zanfi C, Herlenius G +20 more

PubMed

Mitochondrial Hepatopathy.

2022

Clinics in liver disease

Ayers M, Horslen SP, Gómez AM, Squires JE

Plain English
This research focuses on mitochondrial hepatopathies, which are liver diseases caused by problems with the tiny powerhouses in liver cells called mitochondria. The study found that many children with these conditions suffer from worsening health, leading to severe liver issues and high rates of illness and death. While diagnosis has improved with new DNA testing methods, treatments often only provide relief, and new therapies and liver transplants may offer better outcomes. Who this helps: This helps affected children and their families by providing insights into treatment options and improving diagnosis.

PubMed

Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis.

2022

Expert opinion on pharmacotherapy

Bedoyan SM, Lovell OT, Horslen SP, Squires JE

Plain English
This study looked at a new medication called odevixibat for treating progressive familial intrahepatic cholestasis (PFIC), a condition that affects the liver and causes severe itching and bile buildup. The research found that patients taking odevixibat experienced significant improvements, including less itching and lower bile acid levels, with most of the studies lasting between 24 and 72 weeks. While side effects were noted, such as diarrhea and vomiting, odevixibat seems to be a promising option for better managing PFIC. Who this helps: This helps patients with PFIC and their doctors looking for effective treatment options.

PubMed

Frequent Co-Authors

Simon Horslen Philip Rosenthal Ronald J Sokol Kathleen M Loomes Jean P Molleston John C Magee Estella M Alonso Benjamin L Shneider James E Squires

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.